The study found that the failure progression survival of anti-PD1 combined with stereotactic body radiation therapy (SBRT) for metastatic NSCLC was significantly superior to anti-CTLA4 combined with SBRT. Here, CTLA4 is linked to non-small cell lung carcinoma.